Navigation Links
InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
Date:11/7/2012

hat the final procedural step for French pricing and reimbursement of Esbriet had been completed.  The company expects the commercial launch of Esbriet in France in the second half of November 2012. 
  • On October 2, 2012, InterMune announced that Health Canada had approved Esbriet for the treatment of mild to moderate IPF in adult patients.  IPF affects approximately 5,000 to 8,000 Canadians.  InterMune expects to make Esbriet available in Canada starting January 1, 2013 with a commercial organization of approximately 18 to 20 in Canada at the time of launch, including a field force of 10.  Approximately one-third of IPF patients in Canada are covered by private insurance and InterMune expects to secure coverage from substantially all of the private insurance plans in the first half of 2013.  Public (provincial) drug reimbursement plans cover approximately two-thirds of IPF patients and reimbursement from these plans is typically secured within 12 to 18 months of marketing approval.
  • InterMune today announced that the company secured Esbriet pricing and reimbursement in Belgium effective December 1, 2012 and plans to launch Esbriet there in early 2013. The Belgian annualized price of Esbriet is €30,240, or $36,533 at current exchange rates. 
  • InterMune has now concluded successful pricing and reimbursement discussions in nine European countries: Austria, Belgium, Denmark, France, Germany, Iceland, Luxembourg, Norway and Sweden.
  • InterMune today provided an update on the on-going pricing and reimbursement processes for Esbriet in the various European countries:
  • Italy – The company announced today that Esbriet successfully passed the Italian Technical-Scientific Commission review in October.  The company expects to conclude the pricing and reimbursement process in December of 2012 and plans to launch Esbriet in Italy as soon as possible after the process is successfully conc
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune To Release Third Quarter Financial Results On November 7
    2. InterMune To Present At JMP Securities Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune to Present at J. P. Morgan Healthcare Conference
    5. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
    6. PharmAthene Reports Third Quarter 2012 Financial Results
    7. VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting
    8. Patient Safety Technologies Reports Third Quarter 2012 Results
    9. PDI Reports 2012 Third Quarter Financial Results
    10. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    11. Neurocrine Biosciences Reports Third Quarter 2012 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/4/2015)... 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) (the "Company") ... collaborative research program with Emerald Logic, a ... Evolution Technology (FACET), Emerald Logic analyzed Resverlogix,s ... from each of 798 patients who participated ... ASSERT, SUSTAIN and ASSURE. The objective of ...
    (Date:3/4/2015)... , March 4, 2015 Vegalab announced the ... August of last year. As part of the acquisition, ... Koo continuing his role as CEO for the ... Vegalab S.A., will work alongside Koo and oversee developments ... http://photos.prnewswire.com/prnh/20150303/179218 Koo founded Ecowin ...
    (Date:3/3/2015)... SAN DIEGO and TORONTO, March 3, 2015 /PRNewswire/ - ... company developing new therapeutics and molecular diagnostics that target ... for the quarter and seventh-month period ended December 31, ... changed its fiscal year end from May 31 to ... periods we are reporting today are for the quarter ...
    (Date:3/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rcv4lq/gene_therapy ) ... Market, 2015 - 2025" report to their offering. ... provides an extensive study on the marketed and pipeline ... out in this field for over a decade but ... Asian markets; one approved in the EU). There are ...
    Breaking Biology Technology:Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7
    ... Texas, Feb. 6, 2012 Dietary supplements are subject ... the United States, according to a new report published ... article notes numerous authorities to regulate dietary supplements ... Administration (FDA) and the Federal Trade Commission (FTC), as ...
    ... UV Flu Technologies, Inc. ( OTCBB: UVFTD ) ... schedule in its continuing program to eliminate all debt. On February ... and final convertible note, in the amount of $32,500 would be ... made in the last twelve months is nothing short of extraordinary," ...
    ... , a Manchester team lead by Nobel laureates Professor Andre ... dimension in graphene research. Their research shows a transistor that ... next silicon. Graphene one atomic plane of ... from electronic to chemical and from optical to mechanical. ...
    Cached Biology Technology:Dietary Supplements Extensively Regulated, Say Authors of New Article 2Dietary Supplements Extensively Regulated, Say Authors of New Article 3Dietary Supplements Extensively Regulated, Say Authors of New Article 4Dietary Supplements Extensively Regulated, Say Authors of New Article 5UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt 2UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt 3Graphene electronics moves into a third dimension 2
    (Date:3/2/2015)... SAN JOSE, Calif. , March 2, 2015 ... ), the leading developer of human interface solutions, ... ID technology that is designed to enable rapid ... Synaptics Natural ID™ module for gaming is a ... and ODMs the ability to quickly integrate fingerprint ...
    (Date:2/25/2015)... 25, 2015  ABC Financial Services (ABC), the ... Health and Fitness Industry, today announced enhancements to ... The latest upgrade includes advances to the agreement ... check-in via Identity One fingerprint biometrics. The features ... interactive displays at the International Health, Racquet & ...
    (Date:2/24/2015)... Feb. 24, 2015 Research and Markets ... of the "Global 2D Gesture Recognition Market ... The analysts forecast the Global 2D Gesture ... 32.12% over the period 2014-2019 The ... sectors is one of the major trends in ...
    Breaking Biology News(10 mins):Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2
    ... member of the Roche group, and a Yale School ... the company’s Genome Sequencer™ system to identify previously undetectable ... earlier performed clinical trial. The work, presented today ... of Medicine and the VA CT Health Care System, ...
    ... copepods because they prefer to eat colonies of phytoplankton. ... the carbon cycle of cold-water oceans may be a lot ... June 11 in the online version of Proceedings of the ... a common species of saltwater algae – also known as ...
    ... water, including sports drinks, when exercising, a practice ... types of endurance exercise at risk of potentially ... disorders of water metabolism. Such exercise includes marathons, ... condition, known as exercise-induced hyponatremia (EAH), could be ...
    Cached Biology News:454 sequencing identifies HIV drug resistance at early stage 2Marine phytoplankton changes form to protect itself from different predators 2Marine phytoplankton changes form to protect itself from different predators 3Marine phytoplankton changes form to protect itself from different predators 4Runners -- Let thirst be your guide 2Runners -- Let thirst be your guide 3Runners -- Let thirst be your guide 4
    Anti-G-alpha-i 1 G-Protein Host: mouse monoclonal Species Reactivity: human, mouse, rat Applications: WB Storage: 4C...
    ... Gia-1. Strong reactivity ... bovine (74%) and guinea pig ... human (31%). Specificity confirmed ... Gat, rat Goa, rat Gia-1, ...
    KV beta.1 (Q-13)...
    Preadipocyte factor-1 [Pref-1, DLK-1], C-terminal...
    Biology Products: